Press releases
ABG Sundal Collier AB (”ABGSC”) has notified Oncopeptides AB (publ) that stabilisation measures regarding the Company’s shares have been effected
March 22, 2017
OT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, THE UNITED KINGDOM, CANADA, AUSTRALIA, SOUTH AFRICA OR JAPAN
Read more
Additional patent protection for Ygalo granted in Europe until 2032 Regulatory
March 21, 2017
Stockholm - March 21, 2017 - Oncopeptides AB (Nasdaq Stockholm; ONCO) announced today that the European Patent Office (EPO) recently issued a notice that they intend to grant an additional European patent to Oncoeptides AB.The patent (EP2701720) covers inter alia the lyophilized formulation of
Read more
ABG Sundal Collier AB (”ABGSC”) has notified Oncopeptides AB (publ) that stabilisation measures regarding the Company’s shares have been effected. Regulatory
March 13, 2017
NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, THE UNITED KINGDOM, CANADA, AUSTRALIA, SOUTH AFRICA OR JAPAN
Read more
ABG Sundal Collier AB (”ABGSC”) has notified Oncopeptides AB (publ) that stabilisation measures regarding the Company’s shares have been effected. Regulatory
March 2, 2017
NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, THE UNITED KINGDOM, CANADA, AUSTRALIA, SOUTH AFRICA OR JAPAN
Read more
Change in number of shares and votes in Oncopeptides AB (publ) Regulatory
February 28, 2017
During February, the number of shares and votes in Oncopeptides AB (publ) (”Oncopeptides” or the ”Company”) has increased by 16,786,215 shares and votes due to the new issues of shares that were made in connection with the listing of the Company’s shares on Nasdaq Stockholm. As of February 28, 2017, the number of shares and votes in Oncopeptides amounts to 38,828,115
Read more
Company’s CEO Acquires Shares in Oncopeptides Regulatory
February 24, 2017
Stockholm, Sweden - Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today that the company's CEO, Jakob Lindberg acquired 45,000 shares in Oncopeptides for a value of SEK 1.9M in addition to the shares that he subscribed for in the recent share issue in connection with the IPO
Read more
Trading of Oncopeptides AB (publ) on Nasdaq Stockholm commences today
February 22, 2017
NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, THE UNITED KINGDOM, CANADA, AUSTRALIA, SOUTH AFRICA OR JAPAN
Read more
Oncopeptides AB (publ) announces a listing of its shares on Nasdaq Stockholm
February 22, 2017
NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, THE UNITED KINGDOM, CANADA, AUSTRALIA, SOUTH AFRICA OR JAPAN
Read more
Oncopeptides AB (publ) announces a listing of its shares on Nasdaq Stockholm
February 8, 2017
NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, THE UNITED KINGDOM, CANADA, AUSTRALIA, SOUTH AFRICA OR JAPAN
Read more
First patients are now enrolled in HORIZON, Oncopeptides’ Phase II Clinical Trial in Late Stage Relapsed and Refractory Multiple Myeloma
January 19, 2017
Oncopeptides AB, a clinical stage pharmaceutical company, developing the peptidase potentiated therapy Ygalo (melflufen), announced that the clinical development program is continuing according to plan. The company has recently initiated an additional Phase II clinical trial of Ygalo in combination with dexamethasone. The clinical trial is conducted in patients with late stage relapsed and refractory multiple myeloma (RRMM) that are refractory to treatments with pomalidomide and/or daratumumab
Read more